We thus propose that the CD73/adenosine signaling is an attractive therapeutic target for improving the therapeutic gain of RT: we expect that pharmacologic inhibition of CD73/adenosine signaling will not only protect irradiated tissues from early and late adverse side effects of irradiation but block at the same time tumor-promoting effects of CD73/adenosine signaling in the tumor environment and overcome CD73/adenosine-mediated tumor immune escape [42,244]. Here, NT5E is linked to neoplasm.